PT - JOURNAL ARTICLE AU - Hall, Jennifer N. AU - Armitage, Edwin P. AU - Senghore, Elina AU - Darboe, Saffiatou AU - Barry, Momodou AU - Camara, Janko AU - Bah, Sulayman AU - Keeley, Alexander J. AU - McCarthy, James S. AU - Smeesters, Pierre AU - Turner, Claire E. AU - Darton, Thomas C. AU - Marks, Michael AU - Angyal, Adrienn AU - de Silva, Thushan I. TI - Molecular methods enhance the detection of pyoderma-related <em>Streptococcus pyogenes</em> and <em>emm</em>-type distribution in children AID - 10.1101/2024.02.15.24302883 DP - 2024 Jan 01 TA - medRxiv PG - 2024.02.15.24302883 4099 - http://medrxiv.org/content/early/2024/02/17/2024.02.15.24302883.short 4100 - http://medrxiv.org/content/early/2024/02/17/2024.02.15.24302883.full AB - Background Streptococcus pyogenes-related skin infections are increasingly implicated in the development of rheumatic heart disease (RHD) in lower-resourced settings, where they are often associated with scabies. The true prevalence of S. pyogenes-related pyoderma may be underestimated by bacterial culture.Methods A multiplex qPCR for S. pyogenes, Staphylococcus aureus and Sarcoptes scabiei was applied to 250 pyoderma swabs from a cross-sectional study of children &lt;5 years in The Gambia. Direct PCR-based emm-typing was used to supplement previous whole genome sequencing (WGS) of cultured isolates.Results Pyoderma lesions with S. pyogenes increased from 51% (127/250) using culture to 80% (199/250) with qPCR. Compared to qPCR, the sensitivity of culture was 95.4% for S. pyogenes (95% CI 77.2-99.9) in samples with S. pyogenes alone (22/250, 9%), but 59.9% (95% CI 52.3-67.2) for samples with S. aureus co-infection (177/250, 71%). Direct PCR-based emm-typing was successful in 50% (46/92) of cases, identifying 27 emm-types, including six not identified by WGS (total 52 emm-types).Conclusions Bacterial culture significantly underestimates the burden of S. pyogenes in pyoderma, particularly when co-infected with S. aureus. Molecular methods should be used to enhance the detection of S. pyogenes in surveillance studies and clinical trials of preventative measures in RHD-endemic settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a HEFCE/ODA grant from The University of Sheffield (155123) and a Wellcome Trust Intermediate Clinical Fellowship award to TIdS [110058/ Z/15/Z]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Gambia Government/MRC Joint Ethics Committee gave ethical approval for this work (SCC1587).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.